Understanding the Challenge of Novel Psychoactive Substances
The global drug landscape has undergone a dramatic transformation over the past decade, with the illicit drug supply continuing to evolve as novel psychoactive substances (NPS) emerge in response to regulatory efforts. These synthetic compounds, often referred to as designer drugs or research chemicals, represent one of the most significant challenges facing forensic laboratories, law enforcement agencies, and public health officials worldwide. Over the past decade, more than a thousand new psychoactive substances (NPSs) have emerged worldwide, posing significant challenges for drug control, forensic analysis, and public health.
Novel psychoactive substances are deliberately engineered to mimic the effects of controlled substances while circumventing existing drug legislation. NPS are a diverse group of synthetic substances created to mimic the effects of prescription or illicit drugs that are often used non-medically, and may change frequently as legislation to control specific chemical structures or classes of NPS is introduced, with new or modified non-regulated NPS appearing once an NPS has been deemed a controlled substance. This cat-and-mouse game between regulators and illicit manufacturers creates an environment where traditional detection methods struggle to keep pace.
The rapid emergence of novel psychoactive substances (NPSs) after 2020 has created one of the most dynamic analytical challenges in modern forensic science, with hundreds of new synthetic cannabinoids, synthetic cathinones, synthetic opioids, hallucinogens, and dissociatives, appearing as hybrid or structurally modified analogues of conventional drugs, entering the illicit market, frequently found in complex polydrug mixtures. The diversity and complexity of these substances demand innovative analytical approaches that can detect, identify, and characterize compounds even when reference standards are unavailable.
The Current Landscape of Novel Psychoactive Substances
Major Classes of NPS
Novel psychoactive substances encompass several distinct chemical classes, each presenting unique analytical challenges. The major categories include designer opioids, designer benzodiazepines, synthetic cannabinoids, synthetic stimulants, hallucinogens and dissociatives, and a miscellaneous category for substances that don't fit neatly into other classifications.
Designer opioids were the most frequently ordered NPS class, reflecting continued concern for synthetic opioid exposure and overdose risk. These synthetic opioids have been particularly problematic, with new variants continuously appearing on the illicit market. Detection of compounds like N-propionitrile chlorphine increased in late 2025 and early 2026, and has been associated with a number of overdose deaths, but it is not detected with standard screening or POCT and requires specialty testing with few laboratories currently testing for it.
Synthetic cannabinoids (SCs) remain the most prevalent group of new psychoactive substances and continue to dominate forensic seizures worldwide. Synthetic cannabinoids were among the first NPS to appear in the US in the late 2000s, and although commonly referred to as "K2" or "Spice," these substances are sold under numerous other names and are widely available through convenience stores, smoke or tobacco shops, and online marketplaces.
Among synthetic stimulants, substituted cathinones dominated synthetic stimulant detections, with a notable shift in prevalence as N‑isopropyl butylone emerged as the most prevalent synthetic stimulant in 2025. The hallucinogen and dissociative category has also seen significant evolution, with most hallucinogen/dissociative detections attributed to ketamine analogs, particularly 2F-deschloronorketamine and 2F-2-oxo-PCE.
Limitations of Traditional Detection Methods
Conventional drug testing approaches face significant limitations when confronted with the rapidly evolving NPS landscape. Traditional testing panels and IA-only testing approaches are incapable of identifying use of emerging, high-risk substances, with immunoassay (IA)-based testing having recognized limitations, making definitive, mass‑spectrometry–based testing that is routinely updated necessary for accurate identification of NPS exposure in clinical settings.
The fundamental problem with immunoassay-based screening is its reliance on antibody recognition of specific molecular structures. When new analogues appear with even slight structural modifications, these antibodies may fail to recognize the compounds, leading to false negative results. This creates a dangerous situation where individuals may test negative for drugs despite having consumed potent psychoactive substances.
Furthermore, acquiring reference materials for each newly emerging NPS is costly and time-consuming, and libraries are quickly outdated with the emergence of novel analogues. This creates a perpetual challenge for forensic laboratories attempting to maintain comprehensive detection capabilities.
Revolutionary Advances in High-Resolution Mass Spectrometry
The Power of LC-HRMS Technology
Liquid chromatography-high resolution mass spectrometry (LC-HRMS) has been widely used for screening small organic molecules in complex samples, with its selectivity and sensitivity allowing for broad-scope screening of thousands of analytes. This technology represents a paradigm shift in forensic drug analysis, offering capabilities that far exceed traditional methods.
High-resolution mass spectrometry (HRMS) has been identified as the method of choice for broad screening of NPS in a wide range of analytical contexts because of its ability to measure accurate masses using data-independent acquisition (DIA) techniques. The key advantage lies in the instrument's ability to determine the exact molecular mass of compounds with extraordinary precision, often to four or more decimal places.
The main HRMS techniques today are time-of-flight mass spectrometry and Orbitrap Fourier-transform mass spectrometry, with both techniques enabling a range of different drug-screening strategies that essentially rely on measuring a compound's or a fragment's mass with sufficiently high accuracy that its elemental composition can be determined directly. This capability is revolutionary because it allows forensic chemists to identify unknown compounds without necessarily having reference standards available.
Data-Independent Acquisition Strategies
One of the most significant innovations in HRMS technology is the implementation of data-independent acquisition (DIA) methods. The most promising approach to wide-scope analysis in recent years has been UHPLC-HRMS with untargeted data acquisition, such as DIA, with HRMS on an instrument such as a quadrupole time-of-flight (QToF) mass spectrometer offering high sensitivity for low concentrations of analytes in complex mixtures and DIA being well suited for flexible screening and adjustments to the spectral library used for matching as all parent ions are selected for fragmentation and maximum information about a sample is gained.
Unlike traditional targeted methods that only look for specific compounds, DIA approaches fragment all detectable ions in a sample, creating a comprehensive digital record. The acquisition of accurate mass data and analyte-specific MS/MS fragment spectra is essentially creating a digital record of the sample, with improvements in selectivity and sensitivity increasing confidence in NPS identification and enabling retrospective data re-interrogation should new questions or compounds arise in the future.
This retrospective analysis capability is particularly valuable in forensic contexts. When a new NPS is identified in the community, laboratories can re-analyze historical data to determine when the substance first appeared and track its prevalence over time, all without needing to re-run physical samples.
Enhanced Sensitivity and Specificity
The ZenoTOF 7600 system enables accurate and confident detection of potent substances in poly-drug, authentic case samples at trace levels that were not previously achievable. This enhanced sensitivity is crucial for detecting ultra-potent synthetic opioids and other NPS that may be present in biological samples at extremely low concentrations.
Accurate mass and isotopic pattern acts as a filter for confirming the identity of a compound or even identification of an unknown, with high mass resolution being essential for improving confidence in accurate mass results in the analysis of complex biological samples. The combination of accurate mass measurement and isotopic pattern matching provides multiple layers of confirmation, significantly reducing the risk of false positive identifications.
Modern HRMS instruments can distinguish between compounds that differ by as little as 0.001 atomic mass units, allowing differentiation of isobaric compounds that would be indistinguishable using traditional low-resolution mass spectrometry. This capability is essential when analyzing complex biological matrices where multiple substances may be present simultaneously.
Comprehensive Database Development and Management
Building Spectral Libraries
The effectiveness of HRMS-based screening depends heavily on the availability of comprehensive spectral libraries. These databases contain reference spectra for known compounds, including accurate mass measurements, fragmentation patterns, and retention time information. When an unknown compound is detected in a sample, its spectral characteristics can be compared against these libraries to facilitate identification.
The detection of new psychoactive substances has been facilitated by free online tools that can be used to enhance forensic drug screening. These resources have democratized access to critical reference information, allowing laboratories of all sizes to maintain current detection capabilities.
Several international initiatives have emerged to facilitate data sharing among forensic laboratories. These collaborative efforts ensure that when a new NPS is identified in one location, information about its spectral characteristics can be rapidly disseminated to laboratories worldwide. This global approach to database development is essential given the international nature of drug trafficking and the rapid geographic spread of new substances.
SQL Database Archiving for Scalable Analysis
Managing the enormous volumes of data generated by HRMS instruments presents significant challenges. Liquid chromatography-high-resolution mass spectrometry (LC-HRMS) is widely used to detect chemicals with a broad range of physiochemical properties in complex biological samples, however, the current data analysis strategies are not sufficiently scalable because of data complexity and amplitude, leading to the development of a novel data analysis strategy for HRMS data founded on structured query language database archiving, with a database called ScreenDB populated with parsed untargeted LC-HRMS data after peak deconvolution from forensic drug screening data.
The data were acquired using the same analytical method over 8 years, with ScreenDB currently holding data from around 40,000 data files, including forensic cases and quality control samples that can be readily sliced and diced across data layers. This approach to data management enables long-term trend analysis, quality control monitoring, and efficient retrospective searching for newly identified compounds.
The implementation of SQL-based database systems allows forensic laboratories to efficiently query massive datasets, identifying patterns and trends that would be impossible to detect through manual analysis. This capability is particularly valuable for early warning systems that aim to detect emerging drug threats before they become widespread public health problems.
Predictive Filtering and Metabolite Detection
High-resolution mass spectrometry (HRMS) enables non-targeted detection of drugs and metabolites in complex matrices, with phase II metabolites—especially glucuronides—often being the only detectable biomarkers in late or postmortem samples but being underrepresented in commercial libraries, leading to work pursuing the prediction of phase II-glucuronide conjugates in diluted urine samples by non-targeted/targeted LC-HRMS workflows.
The workflow incorporated predictive strategies such as exact mass suspect lists, Structured Query Language (SQL)-based filters, compound-class and diagnostic neutral-loss rules (including the characteristic loss of 176.0321 Da for glucuronides) and MS/MS confirmation using both in-house and public spectral libraries. These sophisticated filtering approaches allow laboratories to identify drug metabolites even when reference standards are unavailable, significantly extending detection windows and improving the sensitivity of toxicological analyses.
The ability to predict and detect metabolites is particularly important in forensic contexts, as parent drugs may be rapidly metabolized and eliminated from the body. By targeting metabolites, forensic chemists can detect drug use that occurred hours or even days before sample collection.
Rapid Screening Technologies for Field Applications
Portable Detection Devices
While laboratory-based HRMS systems provide unparalleled analytical capabilities, there is also a critical need for rapid screening technologies that can be deployed in field settings. Law enforcement officers, emergency responders, and border control agents require tools that can provide preliminary identification of suspected drugs within minutes rather than the hours or days required for comprehensive laboratory analysis.
Portable mass spectrometers and handheld spectroscopic devices have made significant advances in recent years. These instruments, while not offering the same level of performance as laboratory systems, can provide valuable presumptive identification that guides decision-making in the field. When suspicious substances are encountered, rapid screening can help determine appropriate safety precautions, inform medical treatment decisions, and prioritize samples for comprehensive laboratory analysis.
Colorimetric assays remain widely used for field screening despite their limitations. These simple chemical tests produce color changes in the presence of specific drug classes, providing rapid presumptive results. However, they suffer from poor specificity and cannot distinguish between closely related compounds or identify novel analogues. They are best used as an initial screening tool, with all positive results requiring confirmation by more sophisticated analytical methods.
Point-of-Care Testing Innovations
The development of point-of-care testing devices represents an important middle ground between simple field tests and comprehensive laboratory analysis. These systems aim to provide laboratory-quality results in decentralized settings such as emergency departments, drug treatment facilities, and correctional institutions.
Recent innovations in miniaturized analytical devices promise to bring increasingly sophisticated capabilities to point-of-care settings. Microfluidic systems, portable chromatography devices, and compact mass spectrometers are all under development, with some systems already available commercially. These technologies could revolutionize drug testing by providing rapid, accurate results without the delays associated with sending samples to centralized laboratories.
The integration of these portable systems with cloud-based databases and artificial intelligence algorithms could enable real-time identification of unknown substances, with spectral data from field instruments automatically compared against comprehensive reference libraries. This would provide unprecedented capabilities for detecting and responding to emerging drug threats.
Artificial Intelligence and Machine Learning Applications
AI-Driven Structure Prediction
Artificial intelligence (AI) has increasingly been applied to address challenges in NPS design and analysis, with a comprehensive overview of AI methodologies—including deep learning, generative models, and quantitative structure–activity relationship (QSAR) modeling—and their applications in the synthesis, prediction, and identification of NPSs.
The online tool DarkNPS can be used for automatic elucidation of structures of unidentified NPS from mass spectrometric data through a deep learning-enabled approach. This represents a significant advancement in the ability to identify completely unknown compounds. By training neural networks on large datasets of known drug structures and their corresponding mass spectra, these systems can predict the most likely molecular structures for unknown compounds based solely on their spectral characteristics.
Special emphasis is placed on mass spectrometry (MS)-based techniques, where AI algorithms (e.g., for spectral prediction and pattern recognition) are revolutionizing the detection and characterization of unknown NPSs. Machine learning algorithms can identify subtle patterns in spectral data that might be missed by human analysts, improving both the speed and accuracy of compound identification.
Predictive Modeling for Emerging Threats
Generative models (e.g., deep neural networks) are being used to design hypothetical new psychoactive molecules and predict their likely effects, with deep learning and QSAR models able to screen large chemical spaces to flag candidates with high affinities for drug targets (or high toxicity) before they are ever synthesized. While this capability raises concerning questions about the potential for AI to facilitate the design of new drugs of abuse, it also provides valuable intelligence for law enforcement and public health agencies.
By predicting which novel compounds are most likely to appear on the illicit market, laboratories can proactively develop detection methods and acquire reference standards before these substances become widespread. This represents a shift from reactive to proactive drug surveillance, potentially allowing authorities to stay ahead of the curve rather than constantly playing catch-up.
QSAR modeling can also predict the pharmacological properties and toxicity of novel compounds based on their chemical structures. This information is valuable for risk assessment and can inform public health warnings about particularly dangerous substances. Understanding the likely potency and toxicity of new drugs allows for more targeted harm reduction interventions.
Chemometric Analysis and Pattern Recognition
The identification of many compounds within one NPS group has encouraged the development of chemometric and statistical tools such as PCA, hierarchical clustering, canonical discriminant analysis, and automated spectral-similarity metrics, with these approaches not replacing human interpretation but rather translating subtle spectral features into reproducible classifications, and importantly, chemometrics also providing an orthogonal layer of evidence when chromatographic separation is incomplete.
These multivariate statistical approaches are particularly valuable when dealing with complex mixtures or closely related isomers that are difficult to distinguish using traditional analytical methods. By analyzing multiple spectral features simultaneously, chemometric methods can identify patterns that allow for reliable classification and identification even in challenging analytical scenarios.
Machine learning algorithms can be trained to recognize the spectral signatures of specific drug classes, enabling automated classification of unknown compounds. This reduces the burden on human analysts and allows for high-throughput screening of large numbers of samples. As these systems are exposed to more data, their performance continues to improve, creating increasingly powerful tools for drug identification.
Innovative Sample Preparation and Extraction Techniques
Supported Liquid Extraction Methods
Supported liquid extraction (SLE) and UPHLC-HRMS with DIA provide clinical and forensic laboratories a quick, adaptable, and high-throughput screening procedure. Sample preparation is a critical step in forensic drug analysis, as biological matrices such as blood, urine, and tissue contain numerous interfering substances that can complicate analysis.
Supported liquid extraction offers several advantages over traditional liquid-liquid extraction and solid-phase extraction methods. The technique is faster, uses less solvent, and can be easily automated for high-throughput applications. These characteristics make it particularly well-suited for busy forensic laboratories that must process large numbers of samples efficiently.
The simplicity of SLE also reduces the potential for errors during sample preparation, improving the reliability and reproducibility of analytical results. By minimizing the number of manual steps required, laboratories can reduce variability between analysts and improve overall quality control.
Dilute-and-Shoot Approaches
A simply "dilute-and-shoot" qualitative UHPLC-HRMS/MS method (Q Exactive HF, ddMS2) was integrated with Compound Discoverer® software for data processing, with the workflow incorporating predictive strategies such as exact mass suspect lists, Structured Query Language (SQL)-based filters, compound-class and diagnostic neutral-loss rules and MS/MS confirmation using both in-house and public spectral libraries.
Dilute-and-shoot methods represent the ultimate in sample preparation simplicity, involving minimal manipulation of the biological sample before analysis. While this approach increases the complexity of the analytical challenge by introducing more matrix components into the instrument, modern HRMS systems have sufficient selectivity and sensitivity to handle these complex samples effectively.
The advantages of dilute-and-shoot methods include dramatically reduced sample preparation time, lower reagent costs, and the preservation of labile compounds that might be lost during more extensive extraction procedures. These methods are particularly valuable for high-throughput screening applications where speed is essential.
Alternative Biological Matrices
A comprehensive workflow for the detection of drugs and drug metabolites in hair was successfully developed, with easy sample extraction procedure combined with the SCIEX QTRAP 6500+ system shown to enable the sensitive quantitation of a wide range of chemically-diverse analytes in three panels: (1) Novel Psychoactive Substances (NPS), (2) Drugs Of Abuse (DOA) and (3) EtG, a direct alcohol metabolite used as an indicator of alcohol consumption.
Hair analysis offers unique advantages for drug testing, providing a much longer detection window than blood or urine. Drugs and their metabolites are incorporated into growing hair, creating a permanent record of drug exposure that can extend back months or even years depending on hair length. This makes hair analysis particularly valuable for documenting chronic drug use or investigating historical exposure.
Other alternative matrices being explored include oral fluid, sweat, and nails. Each matrix offers distinct advantages and limitations in terms of collection procedures, detection windows, and the types of information that can be obtained. The development of validated analytical methods for these alternative matrices expands the toolkit available to forensic toxicologists and allows for more flexible testing strategies tailored to specific investigative needs.
Emerging Surveillance and Monitoring Strategies
Wastewater-Based Epidemiology
Wastewater-based epidemiology (WBE) has been demonstrated for the early detection of NPS, analyzing 547 samples collected over 12 months from five rest areas and two commercial weigh stations along interstate highways in Kentucky, using a validated ultraperformance liquid chromatography-tandem mass spectrometry method, with several target NPS quantified, including two synthetic opioids (p-fluorofentanyl and metonitazene), a synthetic cannabinoid (MAB-CHMINACA), a phenylpiperazine (mCPP), an alkaloid (mitragynine), and two synthetic cathinones (MDPV and MMMP).
Metonitazene was detected for the first time in 30% of wastewater samples─preceding reports in the state's seized and toxicological data. This demonstrates the potential of wastewater surveillance as an early warning system for emerging drug threats. By monitoring wastewater from strategic locations, public health officials can detect new substances before they become widespread, allowing for proactive interventions.
Wastewater-based epidemiology offers several unique advantages for drug surveillance. It provides objective, population-level data on drug use patterns without relying on self-reporting or clinical encounters. The approach is non-invasive and can provide near-real-time information about drug consumption in specific geographic areas. This makes it particularly valuable for tracking spatial and temporal trends in drug use.
Emergency Department Surveillance Networks
In addition to networks of EDs, other surveillance programs have utilized toxicology data for characterizing new and emerging NPS trends, with the US Drug Enforcement Administration Toxicology Testing Program (DEA TOX) established in 2019 as an NPS surveillance program that collaborates with health departments, law enforcement, poison centers, and hospitals, and analyzes biospecimens from overdose cases to detect NPS exposure, identifying 2378 drug detections in 2022, 282 of which were NPS – 65% of which were opioids and 20% of which were benzodiazepines.
Studies that combine self-report data with toxicology testing in particular are important for capturing unintentional or unknown exposure to NPS including fentanyls and drugs like xylazine, with the harmonization of multiple data sources helping present a more complete picture of both trends involving NPS to better inform public health responses. This integrated approach to surveillance provides richer information than any single data source alone.
Emergency department surveillance is particularly valuable because it captures information about the most serious consequences of drug use. By analyzing samples from overdose cases and other acute intoxications, these programs can identify particularly dangerous substances and drug combinations, allowing for targeted public health warnings and harm reduction interventions.
Drug Checking Services
Drug checking services, where individuals can have substances analyzed anonymously before consumption, represent an innovative harm reduction approach that also provides valuable surveillance data. These programs, which operate in various jurisdictions around the world, use sophisticated analytical techniques to identify the contents of street drugs, alerting users to unexpected or particularly dangerous substances.
From a surveillance perspective, drug checking services provide early warning about new substances entering the illicit market. The data collected through these programs can complement information from law enforcement seizures and clinical toxicology, providing a more complete picture of the drug supply. The real-time nature of drug checking data makes it particularly valuable for rapid response to emerging threats.
The analytical methods used in drug checking services must be rapid, accurate, and capable of identifying a wide range of substances. Many programs use portable or benchtop mass spectrometers, Raman spectroscopy, or other techniques that can provide results within minutes. The integration of these services with broader surveillance networks enhances their value for public health monitoring.
Addressing Analytical Challenges and Limitations
Isomer Differentiation
One of the most challenging aspects of NPS analysis is the differentiation of isomers—compounds with identical molecular formulas but different structural arrangements. Many NPS exist as multiple isomers, which may have dramatically different pharmacological properties and legal status. Distinguishing between these isomers requires sophisticated analytical approaches.
The identification of many compounds within one NPS group has encouraged the development of chemometric and statistical tools such as PCA, hierarchical clustering, canonical discriminant analysis, and automated spectral-similarity metrics. These approaches help analysts distinguish between closely related compounds based on subtle differences in their spectral characteristics or chromatographic behavior.
Ion mobility spectrometry, which separates ions based on their size and shape in addition to their mass, offers another powerful tool for isomer differentiation. When coupled with high-resolution mass spectrometry, ion mobility can provide an additional dimension of separation that allows for more confident identification of structural isomers.
Matrix Effects and Interference
Biological matrices contain numerous endogenous compounds that can interfere with drug analysis. These matrix effects can suppress or enhance the ionization of target analytes, leading to inaccurate quantification or even false negative results. Understanding and controlling matrix effects is essential for reliable forensic drug analysis.
LRMS targeted or untargeted screening procedures ensure sensitivity, but these two cases highlighted situations where their specificity could be insufficient, with isobaric compounds with very similar precursor ions and fragments—which should have led to a false positive result without a secondary analysis by HRMS—being analyzed in the first case. This highlights the importance of using multiple analytical approaches to ensure accurate identification.
Strategies for managing matrix effects include optimizing sample preparation procedures to remove interfering substances, using matrix-matched calibration standards, and employing internal standards that behave similarly to target analytes. The high selectivity of HRMS helps mitigate matrix effects by allowing analysts to distinguish target compounds from interfering substances based on accurate mass measurements.
Quality Assurance and Method Validation
Forensic drug analysis must meet rigorous quality standards to ensure that results are reliable and defensible in legal proceedings. This requires comprehensive method validation, ongoing quality control, and participation in proficiency testing programs. The complexity of HRMS-based methods presents unique challenges for quality assurance.
Method performance measures included those required by ABS Standard 036 "Standard Practices for Method Validation in Forensic Toxicology" for qualitative methods (i.e., interference, carryover, and limit of detection), with extraction recovery, ion suppression or enhancement, and precision also assessed to probe deeper into the strengths and weaknesses of the method.
Establishing appropriate acceptance criteria for HRMS-based identification can be challenging, particularly for non-targeted screening applications. Guidelines have been developed by various professional organizations to provide frameworks for data interpretation and quality assurance. These guidelines address issues such as mass accuracy requirements, the number of diagnostic ions needed for confident identification, and acceptable tolerances for retention time matching.
Regulatory and Legal Considerations
Scheduling and Classification Challenges
The rapid emergence of novel psychoactive substances creates significant challenges for drug scheduling and regulation. Traditional approaches to drug control, which schedule specific chemical structures, are easily circumvented by making minor modifications to create new analogues that fall outside existing regulations. This has led to the development of class-based scheduling approaches that attempt to control entire families of related compounds.
A dedicated section examines the legal and regulatory implications of AI-generated psychoactive substances in the European Union (EU) and United States (USA), highlighting current policies, potential gaps, and the need for proactive regulatory responses. The potential for artificial intelligence to accelerate the development of new psychoactive substances adds another layer of complexity to regulatory challenges.
Forensic laboratories must stay current with changing regulations to ensure that their analytical methods can distinguish between controlled and non-controlled substances. This requires ongoing monitoring of legislative changes and regular updates to analytical methods and databases. The international nature of drug trafficking also necessitates awareness of regulations in multiple jurisdictions.
Admissibility of Evidence
For forensic drug analysis to be useful in legal proceedings, the analytical methods used must be scientifically sound and the results must be presented in a manner that is understandable to judges and juries. The complexity of HRMS-based methods can present challenges in this regard, as explaining concepts like accurate mass measurement and data-independent acquisition to non-scientists requires careful communication.
Courts have generally been receptive to HRMS-based evidence, recognizing the superior capabilities of these methods compared to traditional approaches. However, analysts must be prepared to explain their methods clearly and defend their conclusions under cross-examination. This requires not only technical expertise but also strong communication skills and a thorough understanding of the legal standards for scientific evidence.
Documentation is critical for ensuring the admissibility of forensic evidence. Laboratories must maintain detailed records of all analytical procedures, quality control measures, and data analysis steps. The ability to retrospectively review raw data files is particularly valuable, as it allows for independent verification of results and can address questions that arise during legal proceedings.
International Collaboration and Data Sharing
Early Warning Systems
The global nature of the NPS problem requires international cooperation to effectively monitor and respond to emerging threats. Several early warning systems have been established to facilitate rapid information sharing among countries. These systems allow for the timely dissemination of information about new substances, analytical methods, and public health concerns.
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) operates one of the most comprehensive early warning systems, collecting reports of new psychoactive substances from member states and coordinating risk assessments. Similar systems operate in other regions, with increasing efforts to coordinate these various networks into a truly global surveillance system.
Data standardization is emerging as a methodological priority, especially for sharing cross-border early warning signals about newly detected analogues. Harmonizing data formats and analytical protocols across laboratories and countries facilitates more effective information sharing and allows for better coordination of responses to emerging threats.
Reference Material Sharing
Access to certified reference materials is essential for developing and validating analytical methods for novel psychoactive substances. However, obtaining these materials can be challenging, particularly for newly emerged compounds that may not yet be commercially available. International collaboration in reference material sharing helps address this challenge.
Some organizations have established reference material repositories that make samples available to qualified laboratories for analytical method development. These programs facilitate more rapid development of detection capabilities for new substances. Virtual reference collections, which share spectral data rather than physical materials, provide another approach to addressing the reference material challenge.
The legal and regulatory frameworks surrounding reference materials can be complex, particularly for controlled substances. International agreements and exemptions for analytical purposes help facilitate the legitimate use of these materials for forensic and public health purposes while preventing diversion to illicit use.
Future Directions and Emerging Technologies
Next-Generation Mass Spectrometry
Mass spectrometry technology continues to evolve rapidly, with new innovations promising even greater capabilities for NPS detection. Electron-activated dissociation fragmentation was used to confirm the detection of multiple classes of structurally similar and isobaric novel psychoactive substances, including newly emerging fentanyl opioids, halogenated fentanyl analogs, novel synthetic opioids and synthetic cannabinoids. This advanced fragmentation technique provides more detailed structural information than traditional collision-induced dissociation.
Developments in ion mobility spectrometry, including trapped ion mobility and cyclic ion mobility, offer enhanced separation capabilities that complement mass spectrometry. These technologies provide additional dimensions of separation that can help resolve complex mixtures and distinguish between closely related isomers.
Ambient ionization techniques, which allow for direct analysis of samples with minimal preparation, continue to advance. Methods such as direct analysis in real time (DART) and desorption electrospray ionization (DESI) enable rapid screening of seized materials and other samples, potentially bringing laboratory-quality analysis to field settings.
Integration of Multi-Omics Approaches
The integration of multiple analytical approaches—including metabolomics, proteomics, and genomics—offers new possibilities for understanding drug exposure and effects. These multi-omics strategies can provide comprehensive information about how drugs are metabolized, their mechanisms of action, and their physiological effects.
Metabolomics approaches, which aim to comprehensively characterize all small molecules in biological samples, can identify unexpected metabolites and provide insights into individual variations in drug metabolism. This information is valuable for both forensic investigations and clinical toxicology, helping to explain unusual findings or adverse reactions.
Pharmacogenomic information, which relates genetic variations to drug response, may eventually be integrated into forensic toxicology to provide more complete interpretations of analytical findings. Understanding how genetic factors influence drug metabolism and effects could help explain variations in toxicological findings between individuals.
Blockchain and Distributed Ledger Technologies
Emerging technologies such as blockchain may offer new approaches to data management and information sharing in forensic toxicology. Distributed ledger systems could provide secure, tamper-proof records of analytical results and chain of custody information, enhancing the integrity and defensibility of forensic evidence.
These technologies could also facilitate more efficient sharing of information among laboratories and agencies while maintaining appropriate security and privacy protections. Smart contracts could automate certain aspects of data sharing and quality assurance, ensuring that information is disseminated according to predefined rules and protocols.
The application of blockchain technology to forensic science is still in its early stages, but pilot projects are exploring various use cases. As these technologies mature, they may become important tools for managing the complex data ecosystems required for effective NPS surveillance and detection.
Practical Implementation Strategies for Laboratories
Transitioning to HRMS-Based Workflows
For laboratories considering implementing HRMS-based methods for NPS detection, careful planning is essential. The aim is to provide a review of LC-HRMS drug screening that can help forensic researchers interested in implementing LC-HRMS in their laboratories, and to update general analytical chemists on developments in LC-HRMS drug screening with a focus on how the field has assured scalability for this type of data.
The transition to HRMS requires significant investment in instrumentation, training, and infrastructure. Laboratories must carefully evaluate their needs and resources to select appropriate equipment and develop workflows that fit their specific requirements. This includes considering factors such as sample volume, turnaround time requirements, and the types of matrices that will be analyzed.
Staff training is critical for successful implementation of HRMS-based methods. Analysts must develop expertise in instrument operation, method development, data analysis, and quality assurance. This requires both formal training and hands-on experience. Ongoing professional development is essential to keep pace with rapidly evolving technologies and methodologies.
Balancing Targeted and Non-Targeted Approaches
Non-targeted screening is the only way to detect unknown toxicological substances, but it is labor intensive and therefore best suited for special cases rather than for routine analysis of biological samples, with a real-time non-targeted screening step that could filter out only drug-like features that had never been encountered previously being an ideal supplement for a routine LC-HRMS drug screening workflow, though this may not be achievable with current vendor screening software limitations, with a common analytical approach for emerging drugs in forensic sciences being to curate a list relevant for the region and include the analytes in a targeted data analysis with library entries from reference material.
Most laboratories will benefit from implementing hybrid approaches that combine targeted screening for known compounds with non-targeted capabilities for detecting unknowns. This allows for efficient processing of routine samples while maintaining the ability to identify novel substances when they are encountered.
The specific balance between targeted and non-targeted analysis will depend on the laboratory's mission and the populations it serves. Laboratories supporting law enforcement may prioritize comprehensive screening capabilities, while clinical laboratories may focus more on rapid detection of common drugs with the ability to escalate to more extensive analysis when unusual findings are encountered.
Building Collaborative Networks
No single laboratory can maintain comprehensive capabilities for detecting all possible novel psychoactive substances. Building collaborative networks with other laboratories, academic institutions, and public health agencies enhances collective capabilities and facilitates information sharing. These partnerships can provide access to specialized expertise, reference materials, and analytical capabilities that may not be available in-house.
Professional organizations and scientific societies play important roles in facilitating collaboration and knowledge sharing. Participation in conferences, workshops, and working groups allows analysts to stay current with the latest developments and contribute to the advancement of the field. These forums also provide opportunities to discuss challenges and share solutions with colleagues facing similar issues.
Formal collaborations with academic research groups can provide access to cutting-edge technologies and methodologies before they become commercially available. These partnerships can also support method development and validation efforts, leveraging academic expertise and resources to advance forensic capabilities.
Conclusion: The Path Forward
The challenge posed by novel psychoactive substances represents one of the most dynamic and complex problems in modern forensic science. The rapid emergence and structural diversity of New Psychoactive Substances (NPS) challenge toxicological screening, which usually relies on targeted detection of known compounds, leading to the development of a novel, database-independent analytical workflow capable of anticipating unknown or emerging NPS in complex biological matrices, with a comprehensive workflow combining sample preparation, orthogonal liquid chromatography, and high-resolution tandem mass spectrometry (LC-HRMS/MS) developed for the identification of new structures and their metabolites.
The innovations in forensic chemistry discussed throughout this article—from advanced mass spectrometry techniques to artificial intelligence applications—provide powerful tools for addressing this challenge. However, technology alone is not sufficient. Effective responses to the NPS problem require coordinated efforts among scientists, law enforcement, public health officials, and policymakers.
The use of LC–HRMS in forensic drug screening is expected to continue to grow, and the development of new data analysis workflows and tools will further enhance the accuracy and efficiency of this critical process. As these technologies mature and become more accessible, they will enable more laboratories to implement comprehensive NPS detection capabilities.
The future of NPS detection will likely involve increasingly sophisticated integration of multiple technologies and data sources. Real-time surveillance systems combining wastewater analysis, emergency department monitoring, and law enforcement intelligence will provide early warning of emerging threats. Artificial intelligence will enhance our ability to predict and identify novel compounds. Portable technologies will bring laboratory-quality analysis to field settings.
However, significant challenges remain. The pace of NPS emergence shows no signs of slowing, and the potential for AI to accelerate the development of new psychoactive substances adds new dimensions to the problem. Maintaining adequate resources for forensic laboratories, ensuring access to reference materials, and developing appropriate regulatory frameworks will all be critical for effective responses.
International collaboration will become increasingly important as the NPS problem continues to evolve. Harmonizing analytical methods, sharing data and intelligence, and coordinating regulatory responses across borders will enhance collective capabilities to detect and respond to emerging threats. The development of global standards and protocols will facilitate this collaboration.
Education and training must also evolve to prepare the next generation of forensic scientists for these challenges. Academic programs need to incorporate training in advanced analytical techniques, data science, and artificial intelligence alongside traditional forensic chemistry curricula. Continuing education opportunities must be available to help practicing analysts stay current with rapidly advancing technologies.
Ultimately, addressing the challenge of novel psychoactive substances requires a comprehensive approach that combines technological innovation with effective policy, robust surveillance systems, and coordinated action across multiple sectors. The innovations in forensic chemistry described in this article provide essential tools for this effort, but their full potential will only be realized through sustained commitment and collaboration among all stakeholders.
For more information on drug testing technologies and forensic analysis, visit the United Nations Office on Drugs and Crime and the European Monitoring Centre for Drugs and Drug Addiction. Additional resources on analytical chemistry methods can be found at the American Academy of Forensic Sciences.